Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Maplirpacept - Trillium Therapeutics

Next Previous
X
Search
Drug Profile

Maplirpacept - Trillium Therapeutics

Alternative Names: CD47Fc; PF-07901801; SIRPa-IgG4-Fc; TTI-622

Latest Information Update: 13 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator The Hospital for Sick Children; University Health Network
  • Developer Incyte Corporation; MorphoSys; Pfizer
  • Class Antineoplastics; Immunoglobulin Fc fragments; Immunoglobulin fusion proteins; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action CD47 antigen inhibitors; Phagocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Haematological malignancies
  • Phase I/II Acute myeloid leukaemia; Diffuse large B cell lymphoma; Multiple myeloma; Ovarian cancer
  • Phase I Lymphoma; Non-Hodgkin's lymphoma
  • Preclinical Solid tumours

Most Recent Events

  • 03 Sep 2024 Pfizer terminates a phase I trial in Lymphoma and Multiple myeloma (Late-stage disease, Second-line therapy or greater, Monotherapy, Combination therapy) in USA (IV) not due toany safety concerns, requests from regulatory authorities, changes to the benefit/risk profile or any new concerns regarding the investigational product (NCT03530683)
  • 31 May 2024 Adverse events data from a phase I/II trial in Ovarian cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 15 Feb 2024 Pfizer terminates a phase I/II trial in Ovarian cancer (Combination therapy, Second-line therapy or greater) in USA (IV) due to a business decision was made by Pfizer to terminate and remove the Phase II expansion of this study for administrative reasons (NCT05261490)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top